Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2017-02-14 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (1596 chars) titled 'Total Voting Rights Announcement' issued by Evotec AG on February 14, 2017. It explicitly references Article 26a of the WpHG (German Securities Trading Act) and details a change related to 'Conditional capital increase' and 'Other capital measure', culminating in a 'New total number of voting rights: 146.217.093'. This type of filing, which reports changes in the total number of voting rights or capital structure changes, fits best under the Capital/Financing Update (CAP) category, as it directly relates to the company's capital structure. While it is a regulatory announcement, 'CAP' is more specific than the general 'RNS' fallback. It is not a declaration of voting results (DVA) but a notification of the resulting total rights.
2017-02-14 English
Novo A/S becomes new long-term strategic shareholder in Evotec
Major Shareholding Notification Classification · 99% confidence The document is a press release dated February 9, 2017, announcing that Novo A/S is investing EUR 90.3 million in new Evotec shares via a private placement capital increase. This action directly involves the issuance of new shares and a change in the company's capital structure due to the investment. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves share issuance, it is a specific financing event rather than a general share repurchase (POS) or a broad capital change announcement (SHA), but CAP is the most precise fit for a major equity investment/fundraising announcement.
2017-02-09 English
Novo A/S becomes new long-term strategic shareholder in Evotec
Major Shareholding Notification Classification · 99% confidence The document is an 'Ad-hoc' announcement dated February 9, 2017, disclosing inside information regarding a capital increase where Evotec AG issues new shares to Novo A/S for investment. Key phrases include 'capital increase from its authorised capital against cash,' 'Novo A/S will invest EUR 90.3 m to subscribe shares,' and the resulting increase in share capital. This directly relates to fundraising, financing activities, and changes in capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is relatively short, but it is the primary announcement of the financing event itself, not just an announcement *about* a report.
2017-02-09 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec AG: Release according to Article 26a of the WpHG' and specifically announces the 'Publication of total number of voting rights' as of January 31, 2017. It details a 'Type of capital measure' (Conditional capital increase) and provides the 'New total number of voting rights'. This type of announcement, concerning changes in the total number of shares/voting rights, often falls under capital structure changes or general regulatory disclosures. Since it is a specific regulatory announcement about voting rights and capital structure, it is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS). Given the specific nature related to capital structure (voting rights tied to capital increase), CAP is a strong fit. However, since it is a formal notification under German securities law (WpHG) regarding the total number of shares, and it is not a full report, it aligns closely with specific regulatory disclosures. Reviewing the definitions, 'CAP' covers fundraising/financing/capital structure changes, which this directly relates to (total voting rights). 'RNS' is the fallback. Because the core content is a change in the capital structure/voting rights count, CAP is the most precise fit over the general RNS.
2017-01-31 English
EVOTEC TO ATTEND THREE UPCOMING INVESTOR CONFERENCES
Regulatory Filings Classification · 100% confidence The document is a press release dated January 30, 2017, announcing that Evotec AG management will be presenting at three upcoming investor conferences (Jefferies' 2017 Celgene Collaborators Summit, Bankhaus Lampe German Equity Forum, and 11th ODDO German Conference). This content relates to investor relations activities, specifically scheduling appearances at industry events, which is a form of general corporate communication. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific report (AR, IR). Since it is a general corporate announcement disseminated via DGAP (a service for Regulatory Announcements, Financial/Corporate News and Press Releases) and does not fit into the more specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS.
2017-01-30 English
CYPROTEX, AN EVOTEC COMPANY, EXPANDS INTO NEW UK FACILITY AT ALDERLEY PARK
Regulatory Filings Classification · 100% confidence The document is a press release dated January 26, 2017, announcing that Cyprotex (a subsidiary of Evotec AG) is expanding into a new UK facility at Alderley Park. It contains corporate news, quotes from management, and boilerplate information about the companies involved. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding operational changes and expansion, which fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate news item, as it is disseminated via DGAP (a service for regulatory announcements, financial/corporate news, and press releases). Since it is not a specific financial report, management change (MANG), or capital event (CAP), RNS is the most appropriate fallback for this type of news release.
2017-01-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.